genOway Société anonyme (ALGEN.PA)
EUR 3.92
(0.0%)
EUR 3.92
(0.0%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 982.75 Thousand EUR | -17.09% |
| 2022 | 1.18 Million EUR | 14.9% |
| 2021 | 1.03 Million EUR | -13.71% |
| 2020 | 1.19 Million EUR | 76.74% |
| 2019 | 676.42 Thousand EUR | 24.23% |
| 2018 | 544.47 Thousand EUR | 16.06% |
| 2017 | 469.13 Thousand EUR | -36.45% |
| 2016 | 738.18 Thousand EUR | 73.88% |
| 2015 | 424.53 Thousand EUR | 32.92% |
| 2014 | 319.4 Thousand EUR | -9.75% |
| 2013 | 353.91 Thousand EUR | -55.05% |
| 2012 | 787.39 Thousand EUR | 3.6% |
| 2011 | 760.01 Thousand EUR | 12.48% |
| 2010 | 675.71 Thousand EUR | 80.49% |
| 2009 | 374.38 Thousand EUR | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 Q4 | 982.75 Thousand EUR | 0.0% |
| 2023 Q2 | 1.35 Million EUR | 0.0% |
| 2023 FY | 982.75 Thousand EUR | -17.09% |
| 2022 Q4 | 1.18 Million EUR | 0.0% |
| 2022 Q2 | 1 Million EUR | 0.0% |
| 2022 FY | 1.18 Million EUR | 14.9% |
| 2021 Q2 | 1.37 Million EUR | 0.0% |
| 2021 FY | 1.03 Million EUR | -13.71% |
| 2021 Q4 | 1.03 Million EUR | 0.0% |
| 2020 Q2 | 970.67 Thousand EUR | 0.0% |
| 2020 Q4 | 1.19 Million EUR | 0.0% |
| 2020 FY | 1.19 Million EUR | 76.74% |
| 2019 Q2 | 656.3 Thousand EUR | 0.0% |
| 2019 Q4 | 676.42 Thousand EUR | 0.0% |
| 2019 FY | 676.42 Thousand EUR | 24.23% |
| 2018 Q2 | 503.99 Thousand EUR | 0.0% |
| 2018 FY | 544.47 Thousand EUR | 16.06% |
| 2018 Q4 | 544.47 Thousand EUR | 0.0% |
| 2017 Q4 | 469.13 Thousand EUR | 0.0% |
| 2017 Q2 | 978.34 Thousand EUR | 0.0% |
| 2017 FY | 469.13 Thousand EUR | -36.45% |
| 2016 Q4 | 738.18 Thousand EUR | 0.0% |
| 2016 Q2 | 513.95 Thousand EUR | 0.0% |
| 2016 FY | 738.18 Thousand EUR | 73.88% |
| 2015 FY | 424.53 Thousand EUR | 32.92% |
| 2015 Q2 | 261.7 Thousand EUR | 0.0% |
| 2015 Q4 | 424.53 Thousand EUR | 0.0% |
| 2014 Q4 | 319.4 Thousand EUR | 0.0% |
| 2014 Q2 | 357.95 Thousand EUR | 0.0% |
| 2014 FY | 319.4 Thousand EUR | -9.75% |
| 2013 Q2 | 541.8 Thousand EUR | 0.0% |
| 2013 Q4 | 353.91 Thousand EUR | 0.0% |
| 2013 FY | 353.91 Thousand EUR | -55.05% |
| 2012 FY | 787.39 Thousand EUR | 3.6% |
| 2012 Q4 | 787.39 Thousand EUR | 0.0% |
| 2012 Q2 | 844.77 Thousand EUR | 0.0% |
| 2011 FY | 760.01 Thousand EUR | 12.48% |
| 2011 Q4 | 760.01 Thousand EUR | 0.0% |
| 2011 Q2 | 824.41 Thousand EUR | 0.0% |
| 2010 FY | 675.71 Thousand EUR | 80.49% |
| 2010 Q4 | 675.71 Thousand EUR | 0.0% |
| 2010 Q2 | 543.8 Thousand EUR | 0.0% |
| 2009 Q4 | 374.38 Thousand EUR | 0.0% |
| 2009 Q2 | 496.57 Thousand EUR | 0.0% |
| 2009 FY | 374.38 Thousand EUR | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| ABIONYX Pharma SA | 221 Thousand EUR | -344.684% |
| ABIVAX Société Anonyme | 1.00 EUR | -98275000.0% |
| Adocia SA | 272 Thousand EUR | -261.306% |
| Aelis Farma SA | 53 Thousand EUR | -1754.247% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 1.74 Million EUR | 43.552% |
| IntegraGen SA | 311.44 Thousand EUR | -215.542% |
| Medesis Pharma S.A. | 164.62 Thousand EUR | -496.974% |
| Neovacs S.A. | - EUR | -Infinity% |
| NFL Biosciences SA | -1.1 Million EUR | 188.643% |
| Plant Advanced Technologies SA | 1.22 Million EUR | 19.747% |
| Quantum Genomics Société Anonyme | -119.17 Thousand EUR | 924.622% |
| Sensorion SA | - EUR | -Infinity% |
| Theranexus Société Anonyme | - EUR | -Infinity% |
| TME Pharma N.V. | 91 Thousand EUR | -979.946% |
| Valbiotis SA | 1 Million EUR | 2.214% |
| TheraVet SA | 123.34 Thousand EUR | -696.769% |
| Valerio Therapeutics Société anonyme | 1.00 EUR | -98275000.0% |
| argenx SE | 281.12 Million EUR | 99.65% |
| BioSenic S.A. | - EUR | -Infinity% |
| Celyad Oncology SA | 1.26 Million EUR | 22.004% |
| DBV Technologies S.A. | 1.00 USD | -98275000.0% |
| Galapagos NV | 73.97 Million EUR | 98.672% |
| Genfit S.A. | 4000.00 EUR | -24468.775% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 1.00 EUR | -98275000.0% |
| Innate Pharma S.A. | 1.00 EUR | -98275000.0% |
| Inventiva S.A. | 417 Thousand EUR | -135.672% |
| MaaT Pharma SA | 190 Thousand EUR | -417.237% |
| MedinCell S.A. | -6.71 Million EUR | 114.637% |
| Nanobiotix S.A. | 200 Thousand EUR | -391.376% |
| Onward Medical N.V. | 936 Thousand EUR | -4.995% |
| Oryzon Genomics S.A. | 6029.00 EUR | -16200.398% |
| OSE Immunotherapeutics SA | - EUR | -Infinity% |
| Oxurion NV | 128 Thousand EUR | -667.774% |
| Pharming Group N.V. | 51.38 Million EUR | 98.087% |
| Poxel S.A. | 2.95 Million EUR | 66.754% |
| GenSight Biologics S.A. | 1.00 EUR | -98275000.0% |
| Transgene SA | - EUR | -Infinity% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 1.03 Billion EUR | 99.905% |
| Valneva SE | 44.46 Million EUR | 97.79% |
| Vivoryon Therapeutics N.V. | 1.00 EUR | -98275000.0% |